Safety and Efficacy of Radiotherapy Plus Immunotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
Asia-Pacific Journal of Clinical Oncology · 09.04.2026
DOI: 10.1111/ajco.70116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 09.04.2026. Verfasst von Hasnain Wajeeh Saqib und 8 weiteren Autor:innen. Beteiligte Einrichtung: Riphah International University Islamic International Medical College, Rawalpindi, Pakistan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
The role of combining radiotherapy (RT) with immune checkpoint inhibitors (ICIs) in advanced hepatocellular carcinoma (HCC) remains unclear. We aimed to evaluate the efficacy and safety of RT plus ICI compared to ICI alone.
Methods
We systematically searched PubMed, Web of Science, and Cochrane CENTRAL from inception to April 2025. Eligible studies were clinical trials or retrospective cohorts comparing RT + ICI with ICI alone in patients with advanced HCC. Outcomes included overall survival (OS), progression‐free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment‐related adverse events (AEs). Risk of bias was assessed using ROBINS‐I. Data were synthesized using a random‐effects meta‐analysis.
Results
Eight studies comprising 392 patients were included. RT + ICI was associated with improved outcomes: OS (62.8% vs. 45%), PFS (25.4% vs. 3.6%), ORR (51.1% vs. 27.6%), and DCR (83.1% vs. 60.6%) compared with ICI alone. AEs were more frequent with combination therapy (76.2% vs. 61%). Heterogeneity was moderate to high across several outcomes, and all included studies were retrospective.
Conclusions
RT combined with ICIs shows promising improvements in survival and tumor response compared to ICI alone in advanced HCC, albeit with increased toxicity. Large randomized trials are needed to confirm efficacy, optimize RT regimens, and identify patients most likely to benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Riphah International University Islamic International Medical College, Rawalpindi, Pakistan.
- Shifa College of Medicine, Islamabad, Pakistan.
- Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Zitieren
APA
Saqib, H. W., Khan, M. I., Hayat, T., Haider, S. S. E., Shah, M. I., Nabi, R., Wijdan, S. A., Bashir, R., & Khan, T. (2026). Safety and Efficacy of Radiotherapy Plus Immunotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70116
Vancouver
Saqib HW, Khan MI, Hayat T, Haider SSE, Shah MI, Nabi R, et al. Safety and Efficacy of Radiotherapy Plus Immunotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70116
BibTeX
@article{Saqib2026,
author = {Saqib, Hasnain Wajeeh and Khan, Mustafa Iqbal and Hayat, Tazeem and Haider, Syed Sibt E and Shah, Muhammad Ibrahim and Nabi, Rayyan and Wijdan, Syed Ali and Bashir, Rehman and Khan, Talha},
title = {Safety and Efficacy of Radiotherapy Plus Immunotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70116}
}
EUVIMED